Non-squamous Non-small Cell Lung Cancer Clinical Trials

4 recruiting

Non-squamous Non-small Cell Lung Cancer Trials at a Glance

8 actively recruiting trials for non-squamous non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Ravenna, Birmingham, and Ankara. Lead sponsors running non-squamous non-small cell lung cancer studies include CatalYm GmbH, Sichuan Baili Pharmaceutical Co., Ltd., and Amgen.

Browse non-squamous non-small cell lung cancer trials by phase

Treatments under study

About Non-squamous Non-small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Non-squamous Non-small Cell Lung Cancer? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-squamous Non-small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-squamous Non-small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 2

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
CatalYm GmbH131 enrolled15 locationsNCT07246863
Recruiting
Phase 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled282 locationsNCT06627647
Recruiting
Phase 2

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.80 enrolled1 locationNCT07264816
Recruiting
Phase 3

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Amgen154 enrolled128 locationsNCT06430866
Recruiting
Phase 2

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
CatalYm GmbH107 enrolled25 locationsNCT07098988
Recruiting
Phase 3

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.440 enrolled1 locationNCT07178795
Recruiting
Phase 2

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.170 enrolled1 locationNCT07122687
Recruiting
Phase 2

A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.42 enrolled1 locationNCT06868836